A1 Journal article – refereed

X-Ray Co-Crystal Structure Guides the Way to Subnanomolar Competitive Ecto-5 '-Nucleotidase (CD73) Inhibitors for Cancer Immunotherapy




List of Authors: Sanjay Bhattarai, Jan Pippel, Anne Meyer, Marianne Freundlieb, Constanze Schmies, Aliaa Abdelrahman, Amelie Fiene, Sang-Yong Lee, Herbert Zimmermann, Ali El-Tayeb, Gennady G. Yegutkin, Norbert Sträter, Christa E. Muller

Publisher: WILEY

Publication year: 2019

Journal: Advanced therapeutics

Journal name in source: ADVANCED THERAPEUTICS

Journal acronym: ADV THER-GERMANY

Volume number: 2

Issue number: 10

Number of pages: 8

eISSN: 2366-3987

DOI: http://dx.doi.org/10.1002/adtp.201900075

URL: https://onlinelibrary.wiley.com/doi/full/10.1002/adtp.201900075


Abstract
Ecto-5'-nucleotidase (CD73, EC 3.1.3.5) catalyzes the extracellular hydrolysis of AMP yielding adenosine, which induces immunosuppression, angiogenesis, metastasis, and proliferation of cancer cells. CD73 inhibition is therefore proposed as a novel strategy for cancer (immuno)therapy, and CD73 antibodies are currently undergoing clinical trials. Despite considerable efforts, the development of small molecule CD73 inhibitors has met with limited success. To develop a suitable drug candidate, a high resolution (2.05 degrees A) co-crystal structure of the CD73 inhibitor PSB-12379, a nucleotide analogue, in complex with human CD73 is determined. This allows the rational design and development of a novel inhibitor (PSB-12489) with subnanomolar inhibitory potency toward human and rat CD73, high selectivity, as well as high metabolic stability. A co-crystal structure of PSB-12489 with CD73 (1.85 degrees A) reveals the interactions responsible for increased potency. PSB-12489 is the most potent CD73 inhibitor to date representing a powerful tool compound and novel lead structure.

Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Last updated on 2021-24-06 at 09:52